The ‘protease inhibitor’ are molecules which have many different applications. In some cases, the ‘protease inhibitor’ (PI) indicates a type of drug that is primarily used to treat hepatitis and HIV/AIDS. Proteases are enzymes that cleave or cut proteins. Protease inhibitor inhibits the function of protease, thereby preventing the viral replication. Inhibitors also block the proteolytic cleavage of the precursor protein required for the production of new virus particles. These protease inhibitor drugs, apart from antiviral drugs, can be used in the treatment of cancer and diabetes. Several protease inhibitors can be used as reagents in protein purification or cell/tissue extraction.
The global protease inhibitors market is expected to expand at a significant pace during the forecast period. Development of pharmaceutical protease inhibitor is of great interest which target the specific protease enzyme (for example, in HIV anti-retroviral drugs). Thus, increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C is expected to drive the market during the forecast period. The rising awareness about anti-retroviral therapy and cancer treatment is another major factor contributing to growth of the global protease inhibitors market. Extensive research and development activities in the field of protein purification, pharmacology, animal tissue culture, and molecular biology are expected to drive the global market by 2025. Moreover, surge in the number of pharmaceutical companies, rise in the prevalence of lifestyle diseases, and approval of PI drugs are likely to propel the market during the forecast period. Lack of awareness about PI drugs in developing countries and high cost of protease inhibitor reagents are some of the factors that may restrain the global protease inhibitors market during the forecast period.
The global protease inhibitors market can be segmented based on mechanism of action, application, end-user, and region. Based on mechanism of action, the global market can be divided into serine protease inhibitors, cysteine protease inhibitors, amino peptidase inhibitor, aspartic protease inhibitors, metalloprotease inhibitors, and others. Based on application, the global protease inhibitors market has been divided into commodity protease inhibitor, research tool protease inhibitor, and protease inhibitor drugs. The protease inhibitor drugs segment is expected hold a significant share of the global market from 2017 to 2025, due to high prevalence of anti-retroviral diseases across the world. Based on end-user, the global market has been divided into hospitals & diagnostic centers, pharmaceutical industries, and academic & research institutes.
Geographically, the global protease inhibitors market can be fragmented into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. North America is anticipated to dominate the global protease inhibitors market, during the forecast period, followed by Europe. Factors such as high prevalence of HIV and chronic HCV in the region, growing industrial sector, and advanced health care infrastructure are anticipated to drive the market in North America during the forecast period. Furthermore, in order to strengthen their position in an established market, prominent players are focusing on the region. The market in Asia Pacific is expected to register the maximum growth rate during the forecast period, due to factors such as rising health care expenditure, increasing geriatric population, surging disposable income, high prevalence of chronic diseases, growing focus of global pharmaceutical companies on Asia Pacific, and increasing research activities. Furthermore, rise in awareness about anti-retroviral therapy in regions such as Asia and Africa is driving the global protease inhibitors market.
In order to attain a competitive position in the global market, key players in the protease inhibitors market are engaged in mergers and acquisitions, extensive R&D activities, launch of cost-effective and efficient vaccine products, and collaborative partnerships. Some of the prominent players operating in the global protease inhibitors market are Thermo Fisher Scientific Inc., Sigma-Aldrich, Inc., CYTOSKELETON, INC., Merck & Co., Inc., Genentech, Inc., and Boehringer Ingelheim International GmbH.